Haemonetics Corporation (HAE) Q3 2026 Earnings Call Transcript
Haemonetics Corporation (HAE) Q3 2026 Earnings Call Transcript
Intellia Therapeutics: 2 Major Catalysts Will Determine Stock's Trajectory In 2026
Intellia Therapeutics is reinstated as a Buy, driven by two late-stage in-vivo gene therapy programs: lonvo-z and nex-z. Key 2026 catalysts are the MAGNITUDE clinical hold decision for ATTR-CM and Phase 3 lonvo-z HAE data readout, both with significant valuation impact. Lonvo-z offers potential for a one-time, functional cure in HAE, with strong efficacy and a manageable safety profile, but market adoption hinges on Phase 3 results.
Haemonetics (HAE) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Haemonetics (HAE) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Haemonetics (HAE) Q3 Earnings and Revenues Beat Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.19 per share a year ago.
Haemonetics (HAE) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is it Apt to Retain HAE Stock in Your Portfolio for Now?
Haemonetics' plasma and hemostasis franchises show solid growth potential, but macro headwinds and competition cloud the near-term outlook.
Haemonetics Corporation (HAE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Haemonetics Corporation (HAE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Here's Why Haemonetics (HAE) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Will Haemonetics (HAE) Beat Estimates Again in Its Next Earnings Report?
Haemonetics (HAE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Earn Twice The Yield You Get From Bank On HAE Stock
Currently priced at approximately $80.53 per share, Haemonetics (NYSE: HAE) is trading roughly 7.6% below its 52-week high.
Here's Why Haemonetics (HAE) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
